Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:railway_station
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Ciba-Geigy
gptkb:Ranbaxy_Laboratories |
| gptkbp:activities |
inhibits gastric acid secretion
|
| gptkbp:approves |
gptkb:1988
|
| gptkbp:brand |
gptkb:Prilosec
gptkb:Losec |
| gptkbp:category |
gptkb:C
not recommended |
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:contraindication |
hypersensitivity to omeprazole
concomitant use with certain medications |
| gptkbp:developed_by |
gptkb:temple
|
| gptkbp:duration |
24 hours
as directed by a healthcare provider |
| gptkbp:excretion |
urine
|
| gptkbp:formulation |
suspension
injectable solution enteric-coated tablet delayed-release capsule |
| https://www.w3.org/2000/01/rdf-schema#label |
Omeprazole
|
| gptkbp:ingredients |
C17 H19 N3 O3 S
|
| gptkbp:interacts_with |
gptkb:phenytoin
gptkb:clopidogrel gptkb:warfarin gptkb:diazepam |
| gptkbp:is_atype_of |
A02 B C01
|
| gptkbp:is_available_on |
gptkb:drug
prescription medication |
| gptkbp:is_used_for |
treatment of gastroesophageal reflux disease (GERD)
treatment of peptic ulcers treatment of Zollinger-Ellison syndrome |
| gptkbp:lifespan |
about 1 hour
|
| gptkbp:manager |
oral
intravenous |
| gptkbp:marketed_as |
many countries worldwide
|
| gptkbp:metabolism |
liver
|
| gptkbp:research_focus |
drug interactions
long-term effects alternative therapies |
| gptkbp:safety_features |
long-term use risks
potential bone fractures potential kidney issues potential magnesium deficiency potential vitamin B12 deficiency |
| gptkbp:sales |
over $6 billion annually
|
| gptkbp:side_effect |
headache
nausea abdominal pain diarrhea |
| gptkbp:suitable_for |
children under 1 year without medical advice
patients with liver disease without medical advice patients with certain gastrointestinal conditions without medical advice |
| gptkbp:type_of |
73590-58-6
|
| gptkbp:type_of_care |
important for effectiveness
|